Arcus Biosciences, Inc.
RCUS
Rank in Stocks
#4987
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops... Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The companyโs development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Share Price
$18.95
Last synced: 2026-11-09
Market Cap
$2.68B
Change (1 day)
3.67%
Change (1 year)
-6.60%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Arcus Biosciences, Inc. (RCUS)
Category
Healthcare
Operating Margin for Arcus Biosciences, Inc. (RCUS)
Operating Margin as of November 2026 TTM: -415.38%
According to Arcus Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -415.38%. At the end of 2025 the company had an operating margin of -156.28%.
Operating Margin history for Arcus Biosciences, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -415.38% | 165.79% |
| 2025 | -156.28% | 22.18% |
| 2024 | -127.91% | -55.98% |
| 2023 | -290.60% | 16.24% |
| 2022 | -250.00% | -1,873.05% |
| 2021 | 14.10% | -108.87% |
| 2020 | -158.97% | -73.12% |
| 2019 | -591.39% | -9.95% |
| 2018 | -656.76% | -82.63% |
| 2017 | -3,782.09% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.09% |
US
|
|
| -149.01% | -99.64% |
US
|
|
| 25.57% | -100.06% |
AU
|
|
| 31.23% | -100.08% |
BE
|
|
| 29.35% | -100.07% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Arcus Biosciences, Inc.'s operating margin
What is Arcus Biosciences, Inc.'s operating margin?
Arcus Biosciences, Inc.'s operating margin is -415.38%, as of Nov 2026.
What was Arcus Biosciences, Inc.'s operating margin in 2025?
In 2025, Arcus Biosciences, Inc.'s operating margin was -156.28%, compared with -127.91% in 2024.
How has Arcus Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Arcus Biosciences, Inc.'s operating margin was highest in 2021 (14.10%) and lowest in 2023 (-290.60%).
How does Arcus Biosciences, Inc.'s operating margin compare with similar companies?
Arcus Biosciences, Inc.'s operating margin (-415.38%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.